Simon is Sygnature’s founder, Chief Executive Officer and chair of the Board of Directors.

He is a medicinal chemist with 30 years’ experience in the pharmaceutical industry. Simon has been engaged in the full spectrum of drug discovery activities – from high-throughput screening, to progressing hit-to-lead campaigns and all the way to successful lead optimisation projects and candidate drug selection.

He has a broad experience of research in both a large pharmaceutical company (AstraZeneca) and a mid-size biotech (OSI Pharmaceuticals) as well as in a more commercial environment at CombiPure Ltd., where he was Managing Director and Director of Chemistry.

Simon has a BSc (Hons.) in chemistry and a PhD in synthetic organic chemistry from the University of Nottingham and undertook post-doctoral research at the University of Pittsburgh.


Our board of directors is made up of seasoned industry investors and executives who provide their leadership and experience as we progress our promising pipeline into the clinic.